Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc. ACOR

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.


Recent & Breaking News (NDAQ:ACOR)

Data from First Clinical Trial of GGF2 in Heart Failure Presented at the American College of Cardiology 62nd Annual Scientific Session

Business Wire March 7, 2013

Acorda Therapeutics to Present at the Cowen & Company 33rd Annual Health Care Conference

Business Wire February 25, 2013

Acorda Therapeutics to Present at RBC Capital Markets and Citi 2013 Global Healthcare Conferences

Business Wire February 19, 2013

Acorda Therapeutics Announces Company Intranet Named One of Ten Best in the World

Business Wire February 14, 2013

Acorda Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results

Business Wire February 13, 2013

Acorda Therapeutics Presents GGF2 Preclinical Stroke Data at International Stroke Conference

Business Wire February 7, 2013

Acorda Therapeutics to Present at Leerink Swann Global Healthcare Conference

Business Wire February 7, 2013

Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2012 Financial Results on February 13, 2013

Business Wire February 6, 2013

Free Research Report on ABIOMED, Inc., Acco Brands Corp., Acorda Therapeutics, Inc., Addus HomeCare Corp and First Majestic Silver Corp.

PR Newswire January 31, 2013

Acorda Therapeutics Announces Department of Defense Contract to Support Study of AC105 in Acute Spinal Cord Injury

Business Wire January 24, 2013

Acorda Therapeutics Provides Corporate Update at 31st Annual J.P. Morgan Healthcare Conference

Business Wire January 7, 2013

Biotech Industry Experiencing More FDA New Drug Approvals in 2012

Marketwired January 4, 2013

Free Research Reports on ACOR, F, FST and SPWR Issued by the Bedford Report

Marketwired January 4, 2013

Acorda Therapeutics to Present at the 31st Annual J.P. Morgan Healthcare Conference

Business Wire December 28, 2012

Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition

Business Wire December 21, 2012